Inventor
LAW CHE-LEUNG
US26 patents
⚠️ This page may combine multiple inventors who share the name “LAW CHE-LEUNG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
LAW CHE-LEUNG
7 patentsUS8535678B2Sep 17, 2013
Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
LAW CHE-LEUNG77 citations96
US9051372B2Jun 9, 2015
Anti-CD70 antibody and its use for the treatment of cancer and immune disorders
LAW CHE-LEUNG24 citations92
US8647624B2Feb 11, 2014
Treatment of immune disorders with anti-CD70 antibody
LAW CHE-LEUNG21 citations92
US8337838B2Dec 25, 2012
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
LAW CHE-LEUNG30 citations92
US9345785B2May 24, 2016
Treatment of renal cell carcinoma with anti-CD70 antibody-drug conjugates
LAW CHE-LEUNG23 citations91
US8663642B2Mar 4, 2014
Anti-CD70 antibody-drug conjugates and their use for the treatment and prevention of cancer and immune disorders
LAW CHE-LEUNG44 citations91
US8609104B2Dec 17, 2013
Treatment of B-cell cancers with anti-CD70 antibody-drug conjugates
LAW CHE-LEUNG27 citations91
SEATTLE GENETICS INC
6 patentsUS7491390B2Feb 17, 2009
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
SEATTLE GENETICS INC60 citations97
US7641903B2Jan 5, 2010
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
SEATTLE GENETICS INC45 citations92
US10201615B2Feb 12, 2019
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
SEATTLE GENETICS INC4 citations81
US9708404B2Jul 18, 2017
Anti-NTB-A antibodies and related compositions and methods
SEATTLE GENETICS INC2 citations71
US11607460B2Mar 21, 2023
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
SEATTLE GENETICS INC1 citations70
US10435468B2Oct 8, 2019
Anti-NTB-A antibodies and related compositions and methods
SEATTLE GENETICS INC1 citations61
UNIV WASHINGTON
5 patentsUS11389532B2Jul 19, 2022
Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV PreS1 and/or PreS2, and/or s-HBsAg regions of the HBV envelope protein
UNIV WASHINGTON2 citations71
US11324819B2May 10, 2022
Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen
UNIV WASHINGTON1 citations70
US12285482B2Apr 29, 2025
Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope protein
UNIV WASHINGTON0 citations60
US12496339B2Dec 16, 2025
Therapeutic vaccine for hepatitis b virus (HBV) using the HBV core antigen
UNIV WASHINGTON0 citations59
US11883488B2Jan 30, 2024
Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV core antigen
UNIV WASHINGTON0 citations59
SEAGEN INC
4 patentsUS11202827B2Dec 21, 2021
Dosage and administration of non-fucosylated anti-CD40 antibodies
SEAGEN INC2 citations65
US12496353B2Dec 16, 2025
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
SEAGEN INC0 citations59
US11213584B2Jan 4, 2022
Dosage and administration of non-fucosylated anti-CD40 antibodies
SEAGEN INC0 citations56
US11351269B2Jun 7, 2022
Anti-NTB-A antibodies and related compositions and methods
SEAGEN INC0 citations51